New sponsor requirements add to Indian clinical trial fears
This article was originally published in Scrip
India is said to be putting in place a new requirement in the clinical trials segment, under which sponsors would need to furnish an undertaking of their intent to market the drug under study in India.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.